Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07458529) titled 'Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer' on March 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Seventh Medical Center of PLA General Hospital
Condition:
Rectal Cancer, Adenocarcinoma
Neoadjuvant Therapy
Immunotherapy
Probio-M9
Tislelizumab
Randomized
Intervention:
Combination Product: CRT+PD-1 inhibitor+Probio-M9
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: February 10...